左旋门冬酰胺酶化疗后皮下白脂肪FDG分布改变
一例13岁纵隔T细胞淋巴母细胞淋巴瘤男孩,在 interim 治疗后FDG PET/CT中表现为皮下白脂肪组织弥漫性摄取增高、内脏摄取减低。该分布改变归因于PET/CT前3小时给予化疗酶左旋门冬酰胺酶,影响脂肪细胞氨基酸和葡萄糖代谢,并干扰了治疗反应评估。
要点
- 左旋门冬酰胺酶给药后3小时内行FDG PET/CT可致皮下白脂肪弥漫摄取、内脏摄取减低。
- 该分布改变会干扰淋巴瘤治疗反应评估,应尽量延长化疗与PET/CT间隔。
- 体外脂肪细胞可保护白血病细胞免受左旋门冬酰胺酶作用,提示该分布改变或与耐药相关。
核心结论
- 左旋门冬酰胺酶化疗后短期内行FDG PET/CT可出现皮下白脂肪弥漫性摄取增高和内脏摄取减低的分布改变,并负面影响治疗反应评估。
研究设计与样本
- 单例13岁纵隔T细胞淋巴母细胞淋巴瘤男孩的病例观察,于 interim 治疗后行FDG PET/CT。
主要发现
- FDG PET/CT显示皮下白脂肪组织弥漫性活性增高、内脏活性减低。
- 该分布改变归因于PET/CT前3小时给予左旋门冬酰胺酶,影响脂肪细胞氨基酸和葡萄糖代谢。
- 治疗反应评估受到该分布改变的不利影响。
临床怎么用
- 在连续肿瘤治疗周期中,应尽量延长化疗与PET/CT之间的时间间隔。
局限性
- 仅为单例病例观察,未提供样本量、统计检验或可推广的阈值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A 13-year-old boy with mediastinal T-cell lymphoblastic lymphoma demonstrated an altered biodistribution with diffuse activity in subcutaneous white adipose tissue and decreased visceral activity on interim posttreatment FDG PET/CT. This altered biodistribution was attributed to administration of the chemotherapeutic enzyme l-asparaginase 3 hours preceding the PET/CT, altering adipocytes amino acid and glucose metabolism. Treatment response assessment was adversely affected by the altered biodistribution, emphasizing the importance of maximizing the time between chemotherapy and PET/CT during successive oncologic treatment cycles. Because adipocytes protect leukemic cells in culture from l-asparaginase, we hypothesize that white adipose tissue-altered biodistribution may be related to l-asparaginase resistance.
引用
- Young CR, Kulon ME, Boustani AM, et al. Altered FDG Biodistribution in Subcutaneous White Fat on PET/CT Following l-Asparaginase Chemotherapy. Clin Nucl Med. 2021. PMID: 33086270. doi:10.1097/RLU.0000000000003340
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。